{"title":"JAK 抑制剂的新领域:一名臀部填充物肉芽肿反应患者对托法替尼的显著治疗反应","authors":"Parvin Mansouri, Susan Farshi","doi":"10.1111/jocd.16578","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent research has demonstrated that Janus Kinase (JAK) inhibitors can be effective in treating refractory granulomatous diseases.</p><p><strong>Case presentation: </strong>We report the case of a 50-year-old woman who developed a granulomatous reaction following a filler injection in her buttocks.</p><p><strong>Management: </strong>The patient was treated with tofacitinib, and after 1 year of therapy, the stiffness and swelling resolved without any side effects.</p><p><strong>Conclusion: </strong>Tofacitinib appears to be a viable option for the treatment of granulomatous reactions to fillers.</p>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The New Frontier of JAK Inhibitors: Significant Therapeutic Response to Tofacitinib in a Patient With Granulomatous Reaction to Filler in the Buttocks.\",\"authors\":\"Parvin Mansouri, Susan Farshi\",\"doi\":\"10.1111/jocd.16578\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recent research has demonstrated that Janus Kinase (JAK) inhibitors can be effective in treating refractory granulomatous diseases.</p><p><strong>Case presentation: </strong>We report the case of a 50-year-old woman who developed a granulomatous reaction following a filler injection in her buttocks.</p><p><strong>Management: </strong>The patient was treated with tofacitinib, and after 1 year of therapy, the stiffness and swelling resolved without any side effects.</p><p><strong>Conclusion: </strong>Tofacitinib appears to be a viable option for the treatment of granulomatous reactions to fillers.</p>\",\"PeriodicalId\":15546,\"journal\":{\"name\":\"Journal of Cosmetic Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cosmetic Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/jocd.16578\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jocd.16578","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
The New Frontier of JAK Inhibitors: Significant Therapeutic Response to Tofacitinib in a Patient With Granulomatous Reaction to Filler in the Buttocks.
Background: Recent research has demonstrated that Janus Kinase (JAK) inhibitors can be effective in treating refractory granulomatous diseases.
Case presentation: We report the case of a 50-year-old woman who developed a granulomatous reaction following a filler injection in her buttocks.
Management: The patient was treated with tofacitinib, and after 1 year of therapy, the stiffness and swelling resolved without any side effects.
Conclusion: Tofacitinib appears to be a viable option for the treatment of granulomatous reactions to fillers.
期刊介绍:
The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques.
The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.